Traumatic brain injury represents a substantial global health burden that affects nearly sixty-nine million people annually and stands as a major driver of death, long-term physical disability, and cognitive impairment worldwide. When patients present for emergency neurosurgical intervention, intraoperative physiological stability becomes an urgent clinical focus because anesthetic management directly influences the vulnerable cranial environment. While the primary mechanical impact inflicts instantaneous damage through contusion, skull fracture, intracranial hemorrhage, and diffuse axonal injury, an extensive share of overall neurological damage accumulates gradually over hours and days through secondary injury cascades. These ongoing cascades involve neuroinflammation, disruption of the blood-brain barrier, vascular permeability, oxidative stress, excitotoxicity, and expanding cerebral edema that progressively restrict cerebral blood flow and compress vital intracranial structures.
Because secondary injury pathways remain active and biologically modifiable during operative procedures, perioperative anesthetic management provides a critical window for intervention to maintain intracranial pressure and cerebral perfusion pressure. The cranial vault operates within rigid physical boundaries outlined by the Monro-Kellie doctrine, which dictates that the sum of brain tissue, blood, and cerebrospinal fluid must remain constant inside the non-yielding skull. In severe trauma, inflammatory cellular swelling and acute hematomas exhaust internal compensatory displacement reserves. Once compensatory reserves fail, the injured brain becomes exquisitely vulnerable to minor volume changes, meaning that anesthetic-induced alterations in cerebrovascular resistance, cerebral blood flow, or systemic vascular tone can swiftly escalate intracranial hypertension or induce severe cerebral ischemia.
The normal regulatory mechanisms that protect cerebral perfusion are frequently impaired or entirely abolished following traumatic brain injury, leaving cerebral blood flow passively dependent on fluctuations in systemic arterial pressure. This pathological state fundamentally alters how patients respond to anesthetic agents, as even moderate intraoperative hypotension can drastically undermine cerebral perfusion pressure, defined as the mathematical difference between mean arterial pressure and intracranial pressure. Conversely, unmanaged surges in arterial blood pressure can provoke vasogenic edema and sharp spikes in intracranial pressure when vascular autoregulation is lost. Within this precarious physiological context, anesthetic agents are not interchangeable, as their contrasting effects on metabolic rate, cerebrovascular diameter, and systemic hemodynamics create distinct clinical profiles.
A mini-review published in Frontiers in Neurology by researchers from the Brody School of Medicine at East Carolina University evaluated the physiological differences between propofol and sevoflurane, two of the most widely administered anesthetic agents in neurosurgery. The authors conducted structured searches across PubMed, Elicit, and university library databases through October 2026 without publication-date restrictions, prioritizing clinical trials in acute traumatic brain injury while also synthesizing relevant mechanistic findings from elective craniotomies and experimental animal models. The synthesis revealed that while each agent possesses pronounced physiological characteristics, comparative clinical evidence in acute emergency trauma surgery remains limited, and neither agent has established a definitive, reproducible superiority in improving patient-centered neurological recovery.
Propofol, a widely utilized intravenous sedative acting through the potentiation of gamma-aminobutyric acid neurotransmission, decreases neuronal firing and suppresses cerebral metabolic activity. Under ordinary physiological conditions, propofol couples reduced cerebral metabolic demand with reductions in cerebral blood flow, which in turn reduces intracranial blood volume and facilitates intracranial pressure control and surgical brain relaxation. These metabolic and volumetric reductions make propofol especially appealing when elevated intracranial pressure is present or anticipated. Furthermore, propofol offers rapid onset and predictable offset kinetics, permitting precise titration during delicate operative stages where minute variations in depth influence ventilation, vascular resistance, and cerebral compliance across narrow physiological margins.
Despite its favorable actions on cerebral metabolic suppression and intracranial pressure, propofol carries notable hemodynamic drawbacks that necessitate vigilant monitoring. The drug lowers systemic vascular resistance, frequently precipitating intraoperative hypotension and reductions in mean arterial pressure. If mean arterial pressure drops significantly, reductions in intracranial pressure do not necessarily preserve adequate cerebral perfusion pressure, particularly in patients whose disrupted autoregulation renders cerebral perfusion directly reliant on systemic driving pressure. Additionally, extended high-dose propofol administrations exceeding four to five milligrams per kilogram per hour beyond forty-eight hours carry the risk of propofol infusion syndrome, a rare but life-threatening complication characterized by severe metabolic acidosis, rhabdomyolysis, hyperlipidemia, and cardiovascular collapse.
In contrast, the volatile anesthetic sevoflurane operates primarily through direct, concentration-dependent vasodilation of cerebral resistance vessels, paired with rapid titratability enabled by its low blood-gas partition coefficient. While sevoflurane reduces the cerebral metabolic rate, this reduction may not always match its direct vasodilatory action, potentially producing relative luxury perfusion where cerebral blood flow exceeds metabolic consumption. In patients with severely exhausted intracranial compliance, this concentration-dependent vasodilation presents theoretical concerns because expanding intracranial blood volume could elevate intracranial pressure. Higher concentrations can also induce systemic vasodilation and depress arterial pressure, compounding the threat to cerebral perfusion pressure and demonstrating that sevoflurane cannot simply be assumed to provide greater hemodynamic stability than intravenous regimens.
Direct clinical trials comparing propofol and sevoflurane specifically in traumatic brain injury populations have yielded complex and varied physiological observations. In a prospective randomized study of forty-two severe trauma patients undergoing decompressive craniectomy conducted by Chauhan and colleagues, brain relaxation scores and jugular venous oxygen saturation were comparable between the two agents, while propofol resulted in significantly lower mean arterial pressure. A retrospective cohort study of 340 traumatic brain injury patients by Wu and colleagues observed improved early Glasgow Coma Scale recovery and lower odds of unfavorable Glasgow Outcome Scale scores at hospital discharge among craniotomy patients receiving propofol, but detected no significant outcome differences between agents within the decompressive craniectomy subgroup.
Further clinical ambiguity was highlighted by a prospective randomized trial of 110 adults requiring emergency craniotomy or craniectomy for severe head trauma by Hassan and colleagues, which demonstrated no statistically significant difference in discharge Glasgow Outcome Scale scores between target-controlled propofol and sevoflurane regimens, with good outcomes achieved in 43.6 percent and 41.8 percent of patients, respectively. Broader neurosurgical literature, including meta-analyses by Chui and Liu evaluating thousands of elective craniotomy procedures, generally associates propofol with lower intracranial pressure and reduced brain swelling overall, but meta-analytic subgroup evaluations of emergency craniotomies found no statistically significant difference in intraoperative brain swelling between intravenous and volatile maintenance.
Investigations into secondary injury pathways such as neuroinflammation and cerebrovascular autoregulation similarly reflect inconsistent clinical findings. While experimental animal models demonstrate that propofol attenuates NLRP3 inflammasome activation, pro-inflammatory cytokines, and oxidative stress pathways, and preclinical sevoflurane exposures reveal context-dependent modulation of interleukin-6 and nuclear factor kappa B signaling, human trials have failed to confirm a clear clinical anti-inflammatory superiority for either anesthetic. A randomized trial of craniotomy patients by Markovic-Bozic observed higher interleukin-10 levels with propofol, yet larger systematic reviews in heterogeneous surgical cohorts found no significant overall difference in circulating inflammatory biomarkers, leaving the clinical translation of laboratory findings unverified.
Synthesizing these findings, the review authors propose a hypothesis-generating, physiology-guided framework to assist clinicians in weighing individual patient priorities across intracranial pressure, cerebral perfusion, autoregulatory integrity, baseline hemodynamic stability, and the specific surgical context. Because competing clinical priorities frequently coexist—such as elevated intracranial pressure occurring alongside systemic arterial hypotension—anesthetic selection cannot rely on broad generalizations. Instead, the authors emphasize that anesthetic management represents one interconnected component of comprehensive neurocritical care that requires continuous vigilance, aggressive avoidance of secondary insults, and prospective multicenter randomized validation to establish evidence-based thresholds in acute neurotrauma.
Additional physiological insights emerge from surgical trials evaluating intracranial pressure gradients and physical tissue tension. In a randomized open-label study of 117 patients undergoing elective craniotomy for supratentorial cerebral tumors led by Petersen and colleagues, propofol combined with fentanyl achieved significantly lower subdural intracranial pressure and higher cerebral perfusion pressure than regimens based on sevoflurane or isoflurane. That trial also recorded significantly reduced cerebral swelling following dural opening with propofol, although dural tension differed significantly only in comparison to isoflurane rather than sevoflurane. Similarly, an emergency trial conducted by Preethi and colleagues in 90 adults undergoing evacuation of acute subdural hematomas found that propofol-based total intravenous anesthesia delivered lower intracranial pressure and superior brain relaxation at dural opening and closure compared with isoflurane, even though cerebral perfusion pressure remained comparable between both treatment groups.
Granular assessments of cerebrovascular autoregulation also demonstrate divergent responses across anesthetic depths and monitoring methodologies. In an investigation of non-trauma surgical patients by Conti and colleagues, autoregulatory indices remained preserved under propofol and remifentanil, whereas high-dose sevoflurane diminished autoregulation and accelerated cerebral mean flow velocity during deeper anesthesia. Experimental work in healthy volunteers by Ogawa and colleagues demonstrated impairment of dynamic autoregulation at sevoflurane concentrations as low as 0.5 percent and 1.0 percent. Furthermore, dose-escalation observations in supratentorial tumor surgeries show that increasing sevoflurane from 1.5 percent to 2.5 percent raises cerebral blood flow and reduces cerebrovascular resistance without altering metabolic demand, creating flow-metabolism uncoupling even while carbon dioxide reactivity is preserved.
These complex intraoperative considerations intersect with wider physiological imperatives, including carbon dioxide management and blood-brain barrier integrity. Experimental head trauma models indicate that volatile anesthetics can alter tight-junction protein expression, yet the translational significance for clinical patient recovery remains unverified. Concurrently, precise ventilation control is essential because hypercapnic vasodilation exacerbates intracranial hypertension, while hypocapnia risks precipitating cerebral ischemia. Because current neurosurgical literature lacks validated thresholds for intracranial pressure, mean arterial pressure, or autoregulatory indices, the authors stress that neither propofol nor sevoflurane can be declared universally superior, highlighting the necessity of individualized physiological management in traumatic brain injury.
Subject of Research: Physiological comparison of propofol and sevoflurane anesthesia in traumatic brain injury surgery
Article Title: Integrating physiological considerations in propofol versus sevoflurane anesthesia for traumatic brain injury surgeries
Article References: Ashokkumar, N., Porter, A. B., & Soliman, E. (2026). Integrating physiological considerations in propofol versus sevoflurane anesthesia for traumatic brain injury surgeries. Frontiers in Neurology, 17, 1957394. https://doi.org/10.3389/fneur.2026.1957394
Image Credits: AI Generated
DOI: 10.3389/fneur.2026.1957394
Keywords: traumatic brain injury, propofol, sevoflurane, intracranial pressure, cerebral perfusion pressure, mean arterial pressure, cerebral autoregulation, neuroanesthesia, decompressive craniectomy, craniotomy, cerebral blood flow, brain relaxation, neuroinflammation, cerebral edema, secondary brain injury, hemodynamics

